4 results about "ScFv Antibodies" patented technology

Provided are an scFv antibody that specifically binds Aβ, an isolated nucleic acid encoding the antibody, a vector comprising the nucleic acid, a cell comprising the isolated nucleic acid or the vector, a method for preparing the scFv antibody that specifically binds Aβ, and a use of the scFv antibody that specifically binds Aβ in the preparation of a medicament for treating Alzheimer's disease.

The present invention addresses the problem of providing: lipid nanoparticles that enable selective delivery of a nucleic acid to a target cell; or a method for measuring the optimal density for selective delivery of a nucleic acid to a target cell. Provided are lipid nanoparticles that include: a nucleic acid encapsulated in the lipid nanoparticles; a cationic lipid; a sterol or a sterol derivative; an antibody selected from a VHH antibody, an Fab antibody, and an scFv antibody; a targeting polyalkylene glycol-modified lipid; and a non-targeting polyalkylene glycol-modified lipid. The antibody targets an antigen on a T-cell. The targeting polyalkylene glycol-modified lipid is a lipid in which the antibody is linked to polyalkylene glycol. The non-targeting polyalkylene glycol-modified lipid is a lipid not linked to the antibody. The density of the VHH antibody existing on the surfaces of the lipid nanoparticles in a state capable of binding to the antigen is 0.004-2.300 per 100 nm2 of the nanoparticle surfaces. The density of the Fab antibody existing on the surfaces of the lipid nanoparticles in a state capable of binding to the antigen is 0.003-1.113 per 100 nm2 of the nanoparticle surfaces. The density of the scFv antibody existing on the surfaces of the lipid nanoparticles in a state capable of binding to the antigen is 0.003-1.113 per 100 nm2 of the nanoparticle surfaces.

A monoclonal antibody used for specifically binding to CAR molecules, which is characterized in that the monoclonal antibody comprises a light chain and a heavy chain, the light chain comprises CDR regions having an amino acid sequence as shown in SEQ ID NO: 1-3, and the heavy chain comprises CDR regions having an amino acid sequence as shown in SEQ ID NO: 5-7. By using the described monoclonal antibody or a CAR-T cell detection kit, the steps of CAR-T cell detection are simple, detection time is short, and the detection results are stable. An anti-FMC63 ScFv antibody can reduce the cost of detecting universal anti-CD19 CAR-T cells.

Chimeric antigen receptors (CARs) that are expressible by cells of the immune system such as T cells or NK cells (CAR-T and CAR-NK). These CARs comprise a fragment of scFv antibody directed against a specific antigen of tumor tissues, the tumor activated Trop-2 antigen wherein said activated Trop-2 is the Trop-2 molecule proteolytically cleaved between R87 and T88. The invention also involves the use of CAR constructs for use in anti-tumor cell therapy.